Ph.D., Principal Investigator and CEO, InnoGenomics Technologies, LLC
My scientific interests include a highly sensitive cell-free DNA liquid biopsy assay for Colorectal Cancer patient treatment monitoring. This research was funded by NCI through an SBIR Phase I contract. The highly sensitive, proprietary assay produced significant results when CRC patient samples were compared with controls. This mutation agnostic test has the potential to transform the monitoring of many types of human cancer. InnoGenomics is continuing to develop this kit in collaboration with several highly respected cancer research institutions such as MD Anderson Cancer Center, Jewish General Hospital Montreal and Harvard School of Medicine. An NCI Phase II contract proposal for continued clinical research is pending with the goal of submitting a regulatory application for approval for use in clinical applications. InnoGenomics has seven awarded and several pending patents based on this platform technology. Prior to InnoGenomics, I previously founded and successfully exited from ReliaGene, a forensic DNA testing company.
InnoGenomics Technologies is dedicated to the development of innovative genetic testing solutions that solve crimes and save lives. Their patented technology enables forensic scientists to unlock answers from the most challenging DNA evidence. We are also developing a liquid biopsy method to detect and monitor cancer through a minimally invasive blood test.